Your session is about to expire
← Back to Search
Tau PET Imaging for Alzheimer's Disease (AV1451 ADC Trial)
AV1451 ADC Trial Summary
This trial is measuring the concentration of pathologic tau deposition in the brain using the PET tracer AV-1451 in participants in the UAB-ADC cohort in order to correlate it with demographic, clinical, genetic, and biospecimen data. The primary outcome of this imaging study is to assess interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status.
AV1451 ADC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAV1451 ADC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AV1451 ADC Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You cannot have an MRI or PET scan for medical reasons.You are currently participating in a different research study about amyloid-PET at UAB-ADC.I am not pregnant or have been menopausal for over a year or am surgically sterilized.You are a UAB-ADC study participant.\n
- Group 1: [F-18]AV-1451-PET/MRI
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are enrolled in this medical experiment?
"Affirmative. According to clinicaltrials.gov, this trial has been open since July 8th 2020 and is still recruiting patients today. The research team aims to enrol 160 individuals from a single medical centre."
Is this study still recruiting participants?
"Indeed. According to the information available on clinicaltrials.gov, this study has been open for recruitment since July 8th 2020 and is actively seeking participants as recently updated on July 21st 2022. The goal of this project is to enroll 160 individuals from a single centre."
Is [F-18]AV-1451-PET a reliable method of imaging with minimal risks?
"Limited clinical data exists supporting both the safety and efficacy of [F-18]AV-1451-PET, thus it earned a score of 1."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger